JP7728030B2 - 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物を含む慢性腎疾患の予防または治療用組成物 - Google Patents

抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物を含む慢性腎疾患の予防または治療用組成物

Info

Publication number
JP7728030B2
JP7728030B2 JP2023561148A JP2023561148A JP7728030B2 JP 7728030 B2 JP7728030 B2 JP 7728030B2 JP 2023561148 A JP2023561148 A JP 2023561148A JP 2023561148 A JP2023561148 A JP 2023561148A JP 7728030 B2 JP7728030 B2 JP 7728030B2
Authority
JP
Japan
Prior art keywords
compound
kidney disease
klotho
chronic kidney
oxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023561148A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512813A (ja
JP2024512813A5 (enExample
Inventor
ドン ジュ ジョン
Original Assignee
クロトー サイエンシーズ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020220040453A external-priority patent/KR102463786B1/ko
Application filed by クロトー サイエンシーズ カンパニー リミテッド filed Critical クロトー サイエンシーズ カンパニー リミテッド
Publication of JP2024512813A publication Critical patent/JP2024512813A/ja
Publication of JP2024512813A5 publication Critical patent/JP2024512813A5/ja
Application granted granted Critical
Publication of JP7728030B2 publication Critical patent/JP7728030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023561148A 2021-04-01 2022-04-01 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物を含む慢性腎疾患の予防または治療用組成物 Active JP7728030B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2021-0042955 2021-04-01
KR20210042955 2021-04-01
KR10-2022-0040453 2022-03-31
KR1020220040453A KR102463786B1 (ko) 2021-04-01 2022-03-31 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물
PCT/KR2022/004706 WO2022211574A1 (ko) 2021-04-01 2022-04-01 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물

Publications (3)

Publication Number Publication Date
JP2024512813A JP2024512813A (ja) 2024-03-19
JP2024512813A5 JP2024512813A5 (enExample) 2024-04-01
JP7728030B2 true JP7728030B2 (ja) 2025-08-22

Family

ID=83456608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561148A Active JP7728030B2 (ja) 2021-04-01 2022-04-01 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物を含む慢性腎疾患の予防または治療用組成物

Country Status (8)

Country Link
US (1) US12691102B2 (enExample)
EP (1) EP4317140A4 (enExample)
JP (1) JP7728030B2 (enExample)
CN (1) CN117157280B (enExample)
AU (2) AU2022248891A1 (enExample)
BR (1) BR112023020026A2 (enExample)
CA (1) CA3213910A1 (enExample)
WO (1) WO2022211574A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538123A (ja) 2002-08-07 2005-12-15 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アシルアミノ−置換複素芳香族化合物および医薬としてのそれらの使用
US20130090480A1 (en) 2010-06-18 2013-04-11 Hea Young Park Choo Benzoxazole Derivatives Having Inhibitory Activity Against Interleukin-6, Preparation Method Thereof, and Pharmaceutical Composition Containing the Same
JP2013514366A (ja) 2009-12-16 2013-04-25 イーライ リリー アンド カンパニー 可溶性α−ＫＬＯＴＨＯの治療的使用
WO2016176473A1 (en) 2015-04-28 2016-11-03 Sanford-Burnham Medical Researc Institute Apelin receptor agonists and methods of use thereof
KR20170024522A (ko) 2015-08-24 2017-03-07 이화여자대학교 산학협력단 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
JP2023503217A (ja) 2019-10-02 2023-01-27 克洛索科学公司 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物およびその用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088770A (en) * 1971-05-04 1978-05-09 Eli Lilly And Company Substituted 2-anilinobenzoxazoles used as immunosuppressive agents
PL357678A1 (en) * 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators
US8318703B2 (en) * 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
US20070066577A1 (en) * 2003-04-03 2007-03-22 Hea Young Park Choo Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
KR101446301B1 (ko) * 2013-04-11 2014-10-06 서울대학교산학협력단 Cxcr3/cxcl10 길항제 화합물, 이의 제조방법 및 이를 포함하는 골 전이의 예방 및 치료용 약학 조성물
WO2018087132A1 (en) * 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP3611521B1 (en) 2018-08-16 2026-05-27 GE Vernova Technology GmbH Apparatus for monitoring a condition of an electrical power transmission medium
IT201900007446A1 (it) * 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
KR20200145909A (ko) 2019-06-20 2020-12-31 주식회사 레이지소사이어티 면도날 자동주문 장치
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538123A (ja) 2002-08-07 2005-12-15 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アシルアミノ−置換複素芳香族化合物および医薬としてのそれらの使用
JP2013514366A (ja) 2009-12-16 2013-04-25 イーライ リリー アンド カンパニー 可溶性α−ＫＬＯＴＨＯの治療的使用
US20130090480A1 (en) 2010-06-18 2013-04-11 Hea Young Park Choo Benzoxazole Derivatives Having Inhibitory Activity Against Interleukin-6, Preparation Method Thereof, and Pharmaceutical Composition Containing the Same
WO2016176473A1 (en) 2015-04-28 2016-11-03 Sanford-Burnham Medical Researc Institute Apelin receptor agonists and methods of use thereof
KR20170024522A (ko) 2015-08-24 2017-03-07 이화여자대학교 산학협력단 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
JP2023503217A (ja) 2019-10-02 2023-01-27 克洛索科学公司 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物およびその用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Frontiers in endocrinology，2020年，Vol.11, No.560，pp.1-15

Also Published As

Publication number Publication date
WO2022211574A1 (ko) 2022-10-06
AU2025202595A1 (en) 2025-05-01
AU2022248891A1 (en) 2023-10-26
CA3213910A1 (en) 2022-10-06
AU2022248891A9 (en) 2023-11-09
EP4317140A4 (en) 2025-04-09
CN117157280B (zh) 2026-07-21
JP2024512813A (ja) 2024-03-19
US12691102B2 (en) 2026-07-28
US20240216341A1 (en) 2024-07-04
CN117157280A (zh) 2023-12-01
BR112023020026A2 (pt) 2024-01-23
EP4317140A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
JP7412546B2 (ja) 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物およびその用途
JP7728031B2 (ja) 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物を含む退行性神経疾患の予防または治療用組成物
EA016360B1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1, фармацевтическая композиция на их основе и их применение
AU2025202595A1 (en) Composition for preventing or treating chronic kidney disease, comprising compound that induces expression of anti-aging gene klotho
KR102463786B1 (ko) 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물
KR20150080425A (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
US20070066577A1 (en) Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
KR20230008908A (ko) 신규 메틸설폰아미드 유도체 화합물의 암전이 억제용 조성물
JP7803597B2 (ja) 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する新規化合物
KR20070097108A (ko) 헤테로시클릭 옥심 유도체, 이의 제조 방법 및 이의혈당강하제 또는 지질감소제로서의 용도
KR102580387B1 (ko) 신규한 피라졸로[3,4-b]피리딘 유도체를 포함하는 비만 및 당뇨병을 비롯한 대사성질환 또는 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
KR20230019801A (ko) 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물
KR20140120903A (ko) 여포 자극 호르몬수용체의 아고니스트로서 중수소화 티아졸리디논 유사체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250618

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250804

R150 Certificate of patent or registration of utility model

Ref document number: 7728030

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150